The IRE Resource Center is a major research library containing more than 23,250 investigative stories — both print and broadcast. These stories are searchable online or by contacting the Resource Center directly (573-882-3364 or rescntr@ire.org) where a researcher can help you pinpoint what you need. Browse or search the tipsheet section of our library below. Stories are not available for download but can be easily ordered by contacting the Resource Center:
Search results for "Tour de France" ...
-
60 Minutes: Armstrong
"This story uncovers new evidence about accusations that have long haunted cyclist Lance Armstrong: that he was using performance enhancing drugs when he won the Tour de France. What was found was new information surrounding a federal grand jury that is now investigating whether Armstrong led a systematic doping program when he was captain of the U.S. team."
Tags: Lance Armstrong; performance enhancing drugs; Tour de France; broadcast
-
Has something to get off his chest
Texas Monthly profiles elite cyclist Lance Armstrong, the two-time Tour de France winner. "He doesn't use performance-enhancing drugs, he insists, no matter what his critics in the European press and elsewhere say. And yet the accusations keep coming," the magazine reports. The story depicts Lance's battle with testicular cancer, which had spread to his lungs and brain. The article examines how the use of EPO - a drug that saved Lance from cancer - and other dopes can enhance performance, and reveals how riders have always been a step ahead of the testers. A major finding is that "dopers enjoy a solidarity that is maintained by a code of silence."
Tags: Tour de France; doctors; drugs; doping; cycling; riding; tournaments; sponsors; champions; drug abuse; the Games; Olympics; muscles; Human Performance Laboratory at the University if Texas in Austin
-
Breakfast Of Champions
The New Times reports on the abuse of the hormone EPO by athletes, especially elite cyclists. EPO, made by Amgen, raises the amount of oxygen the blood can carry. There isn't any test to detect it yet because it mimics the natural human hormone too closely. The company, which makes $3 billion a year, is not taking any steps to combat the use of EPO, such as putting a marker in it that could be detected. The Tour de France and other major sporting events have been rocked by scandal related to EPO use, but still little pressure is being put on pharmaceutical companies to prevent abuse.
Tags: Tour de France; drugs; EPO; Amgen